Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arena Rises With Post-Belviq Pipeline

Executive Summary

Arena's valuation rose more than four-fold in 2017. CEO Amit Munshi discusses his plans for lead programs ralinepag and etrasimod following cost cutting and fundraising, and handing over rights to weight loss product Belviq to Eisai.

Advertisement

Related Content

Finance Watch: In Obesity, Vivus Raises Cash For Deals, Orexigen Finds A Buyer
Finance Watch: The Curious Case Of Proteostasis' Short Attack
If Orexigen Disappears, Who's Left In The Obesity Market?
Arena Rises, But Raises Questions With Phase II Ralinepag Data In PAH
Beyond Belviq: Reinventing Arena To Focus On Phase II Candidates
Deal Watch: Taking Care Of Business Before J.P. Morgan

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100287

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel